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Abstract
Introduction Gastrointestinal stromal tumors (GISTs) are
mesenchymal tumors of the gastrointestinal tract, which are
characterized in the majority of cases by activating mutations
in KIT and platelet-derived growth factor receptor alpha
(PDGFRA). The introduction of tyrosine kinase inhibitors
has revolutionized the management of patients with metastatic
GIST. However, complete surgical resection remains the
mainstay of management for those with localized disease.
Recently, three large trials have confirmed the benefit of
adjuvant imatinib therapy in patients who were at high risk
of recurrence following complete resection. In this setting, it is
critical that oncologists understand the various GIST risk
assessment criteria and be able to apply these methods to
accurately assess the risk of recurrence and the need for
adjuvant imatinib therapy.
Purpose The aim of this review is to outline the risk stratifi-
cation systems currently available to oncologists who are
treating patients with GIST, so they can be optimally applied
for clinical decision-making.
Keywords Gastrointestinal stromal tumors . GIST . Risk .
Risk assessment . Imatinib . Adjuvant therapy
Background
Gastrointestinal stromal tumors (GISTs) are the most common
mesenchymal tumors of the gastrointestinal tract. The intro-
duction of the tyrosine kinase inhibitor, imatinib, has revolu-
tionized the management of metastatic GIST. The most
common primary sites for such tumors are the stomach
(60%) and small intestine (25–35%), although they can occur
anywhere along the gastrointestinal tract [1, 2]. Resection
remains the mainstay of management for patients with local-
ized disease; however, despite adequate resection, there is
varying risk of recurrence, ranging from negligible for those
with very small GISTs to well over 50 % [2, 3]. Over the last
few years, imatinib has shown utility in the adjuvant setting,
with the publication/presentation of three randomized trials
showing the benefit of adjuvant therapy [4–6]. Consequently,
it is clear that accurate and reproducible methods are required
to discuss the potential benefits and risks of adjuvant systemic
therapy with patients. The majority of patients with low-risk
GIST have a favorable outcome after resection and should not
receive adjuvant therapy. Over the last decade, several risk
stratification systems for resected GIST have been proposed.
In addition, others have suggested the use of prognostic no-
mograms for individualized risk assessment, and mutational
status may also have relevance. The aim of this review is to
provide a practical guide to the available strategies for risk
assessment in GIST.
Trials of Adjuvant Imatinib
With the publication/presentation of three large randomized
trials showing benefit for the administration of adjuvant ima-
tinib, accurate and reproducible methods for risk assessment
have gained increasing clinical importance.
The American College of Surgeons Oncology Group
(ACOSOG) phase II Z9000 trial assessed the safety and
efficacy of 1 year of adjuvant imatinib [6]. This single-arm,
open-label, phase II trial enrolled 107 patients with GISTwho
were at high risk of recurrence following complete resection
(tumor size >10 cm, tumor rupture, or <5 peritoneal metasta-
ses). With a median follow-up of 7.7 years, 57 of the 106
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patients (54%) had developed recurrent disease and 28 (26%)
had died. Only four patients developed recurrence during the
first year. The 1-, 3-, and 5-year recurrence-free survival
(RFS) rates were 96, 60, and 40%, respectively, with amedian
RFS of 4 years. The 1-, 3-, and 5-year overall survival (OS)
rates were 99, 97, and 83 %, respectively, and the median OS
has not been reached.
The ACOSOG Z9001 phase III trial randomized 713 pa-
tients with tumors ≥3 cm in size to receive either imatinib
400 mg/day or placebo for 1 year after surgery [4]. Accrual to
this trial was stopped after the planned interim analysis
showed that imatinib significantly improved RFS. At 1 year,
RFS was 98 % in the imatinib arm and 83 % in the placebo
arm (hazard ratio (HR), 0.35; 95 % confidence interval (CI),
0.22 to 0.53; p<0.0001). Moreover, significant RFS benefit
with imatinib was seen in patients at high risk of recurrence
(tumor size ≥10 cm) as well as those at intermediate risk
(≥6 to <10 cm). With a median follow-up of 19.7 months,
no difference in OSwas observed between the two arms, but it
should be noted that crossover to the imatinib arm was
allowed on the development of recurrent disease. Imatinib
was well tolerated in this trial. Based on these results, in
2008 the US Food and Drug Administration (FDA) granted
accelerated approval of adjuvant imatinib for treatment of
KIT-positive GIST, with full approval in 2012. Adjuvant
imatinib was also approved in 2009 by the European
Medicines Agency (EMA) for KIT-positive GISTwith signif-
icant risk of relapse.
The fact that many recurrences were observed in this trial
after completion of adjuvant imatinib (i.e., approximately
50 % of the tumors ≥10 cm in size recurred during the first
3 years after randomization) suggests that some patients may
benefit from a longer duration of therapy. Subsequently,
the Scandinavian Sarcoma Group/Arbeitsgemeinschaft
Internistische Onkologie trial XVIII (SSG XVIII/AIO) ran-
domized 400 patients with GIST to receive 12 or 36months of
imatinib 400 mg/day after surgical resection of primary tu-
mors [5]. Patients with a high estimated risk of recurrence
according to the modified National Institutes of Health (NIH)
criteria (i.e., with at least one of the following characteristics:
longest tumor diameter >10 cm, mitotic count >10 mitoses per
50 high-power fields (HPF), tumor diameter >5 cm, and
mitotic count >5 or tumor rupture) were enrolled in the trial.
Patients randomized to 36 months of imatinib had significant-
ly longer RFS compared with those randomized to 12 months
of therapy (5-year RFS, 65.6 vs. 47.9 %, respectively; HR,
0.46; 95 % CI, 0.32 to 0.65; p<0.0001). Those who were
treated with 36 months of adjuvant imatinib also had signifi-
cantly longer OS compared with patients who received
12 months of treatment (5-year OS, 92 vs. 82 %; HR, 0.45;
95 % CI, 0.22 to 0.89; p=0.02). More discontinuations were
noted in the 36-month group for reasons other than GIST
recurrence compared with the 12-month group (51 [25.8 %]
vs. 25 patients [12.6 %], respectively). Discontinuation due to
adverse events occurred in 13.6 % of patients in the 36-month
arm compared with 7.5 % in the 12-month arm.
Consequently, the National Comprehensive Cancer Network
(NCCN) and the European Society of Medical Oncology
(ESMO) recommend that 36 months of adjuvant imatinib be
considered in patients with intermediate- or high-risk tumors [7,
8]. In addition, the FDA and EMA have both updated the label,
extending the duration of adjuvant imatinib to 36 months in
patients with GISTwho are at high risk of recurrence.
Recently, the results of a trial of 900 patients with
intermediate- or high-risk resected GIST, who were random-
ized to receive 2 years of adjuvant imatinib or no adjuvant
therapy, have been presented [9]. Patients were stratified by
NIH risk criteria, tumor site, and margin status. This trial
confirmed the significant benefit of adjuvant imatinib on
RFS. The 3-year RFS was 84 and 66 % in the imatinib and
the no adjuvant therapy arms, respectively (p<0.001).
Similarly, the 5-year RFS was 69 and 63 %, respectively
(p<0.001). These investigators have proposed the use of a
novel endpoint, imatinib failure-free survival (IFS), defined as
the time to when a different tyrosine kinase inhibitor is started.
In the high-risk subgroup, a non-statistically significant trend
in favor of the adjuvant imatinib was observed in terms of IFS.
The ongoing, non-randomized, single-arm, phase II Post-
resection Evaluation of Recurrence-free Survival for
gastroIntestinal Stromal Tumors (PERSIST-5) trial is evaluat-
ing the efficacy and safety of long-term adjuvant imatinib in
patients who are at significant risk for recurrence following
complete resection of primary GIST (NCT00867113).
Administration of oral imatinib 400 mg/day is planned for
up to 5 years or until progression, relapse, or intolerance. The
primary endpoint of this trial is RFS.
Risk Stratification Systems
NIH Consensus Criteria
The NIH GIST Consensus Criteria were developed by
Fletcher et al. [10]. The risk categories proposed by these
criteria are shown in Table 1. These criteria utilize two clinical
pathological factors, tumor size and mitotic count, allowing
recurrence risk to be stratified as very low, low, intermediate,
or high. Although the NIH criteria were not derived from
actual clinical trial data, subsequent retrospective studies of
patients with localized GIST treated with surgery alone have
confirmed the prognostic value of both tumor size and mitotic
count. A study by the Spanish Group for Sarcoma Research
(GEIS) of 162 patients with GIST, treated between 1994 and
2001, found that in a multivariate analysis for RFS, the pres-
ence of high cellularity and deletions in codons 557–558
within KIT exon 11 were associated with recurrence [11].
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Similarly, DeMatteo et al. evaluated 107 patients with
localized GIST treated between 2001 and 2003 [12].
Multivariate analysis of factors predictive of recurrence in
this and the subsequent phase III adjuvant imatinib trial
found that mitotic rate ≥5, tumor size ≥10 cm, and primary
tumor location were independent factors. A number of
other studies have confirmed the prognostic importance of
tumor site [3, 13–15]. Furthermore, the prognostic utility of
the NIH criteria has been confirmed in six large cohort
studies [16–20]. The NIH criteria clearly are useful and
applicable, despite the fact that tumor site is not included as
a prognostic factor in this system.
American Forces Institute of Pathology Criteria
The American Forces Institute of Pathology (AFIP) criteria
were developed by analyzing a large data set of patients with
long-term follow-up [2, 18, 21, 22]. GISTs arising from the
stomach have generally better prognosis than those arising
from the small bowel or rectum; consequently, the AFIP
criteria incorporate tumor site as well as tumor size andmitotic
count (Table 2). Tumor size is categorized into four groups:
<2 cm, >2 to ≤5 cm, >5 to ≤10 cm, and >10 cm. Mitotic count
is classified into two groups: ≤5 or >5 mitoses per 50 HPF.
Tumor sites identified in this classification are stomach, duo-
denum, ileum/jejunum, and rectum.
Modified NIH Criteria (Joensuu Risk Criteria)
Joensuu has proposed a modified version of the NIH risk assess-
ment system that also includes tumor location and rupture as
high-risk factors [23]. This system utilizes four prognostic fac-
tors: tumor size, mitotic count, tumor site, and tumor rupture
(Table 3). Several studies have documented the high risk of
recurrence associated with tumor rupture in GIST [17, 18, 24].
Often tumors that are large and have a non-gastric location tend
to rupture, but nonetheless, tumor rupture has independent prog-
nostic information over size, site, and mitotic count [23]. An
important point to note is that this system classifies patients with
small (≤5 cm), non-gastric GISTs and mitotic counts >5 per 50
HPF and those with non-gastric tumor sizes between 5.1 and
10 cm and <5 mitoses per 50 HPF as having a high risk of
recurrence (in contrast to the NIH system).
Joensuu et al. performed a pooled analysis of 2,560 patients,
who had undergone surgery alone for GIST, from 10 studies
comparing the three risk stratification systems described above
[14]. They found that large tumor size, high mitotic count, non-
gastric primary site, tumor rupture, and male sex were inde-
pendent adverse prognostic factors. The analysis revealed that
all three risk stratification systems were strongly associated
with RFS. The authors also observed that most recurrences
occurred within the first 5 years after surgery, but occasionally
late recurrences were seen. Joensuu et al. also evaluated prog-
nostic contour heat maps using continuous non-linear modeling
of tumor size and mitotic count with incorporation of tumor site
and rupture. Contour maps were more accurate than the risk
stratification systems in predicting risk of recurrence (receiver
operating characteristic (ROC) curve analysis: area under the
ROC curve, 0.88; 0.86–0.90) [14].
It has been suggested that other tumor characteristics, in-
cluding infiltration of adjacent structures, serosal invasion,
necrosis, high cellularity, and tumor vascularity, could be
utilized as risk factors [25]. However, these characteristics
are currently not routinely used.
Prognostic Nomograms
In an attempt to individualize risk of recurrence, Gold et al. [3]
and Rossi et al. [24] have proposed two nomograms for risk
assessment in patients with resected GIST. Gold et al. devel-
oped a nomogram to predict RFS in a data set of 127 patients
who were treated at a single institution [3]. The nomogram
incorporates size, mitotic index, and tumor site to predict 2-
and 5-year RFS. This nomogram has been validated in two
external series: GEIS (N=212) and the Mayo Clinic (N=148)
data sets. Of note, this nomogram categorizes mitotic count as
either ≤5 or >5 mitoses per 50 HPF.
The nomogram proposed by Rossi et al. is also based on
tumor size, mitotic count, and tumor site. In contrast to the Gold
nomogram, however, tumor size and mitotic index are included
as continuous variables [24]. This nomogram was developed
through a retrospective analysis of 929 patients treated at 35
Italian centers between 1980 and 2000. It may be used to
predict OS; however, this nomogram has not been externally
validated. In addition, due to the lack of complete information
on recurrence, this nomogram cannot be used to predict RFS.
Table 1 NIH-Fletcher criteria for GIST risk assessment
Risk category Primary tumor size (cm)a Mitotic count
(per 50 HPF)b
Very low risk <2 <5
Low risk 2–5 <5
Intermediate risk <5 6–10
5–10 <5
High risk >5 >5
>10 Any mitotic rate
Any size >10
Adapted with permission from Fletcher et al. [10]
GIST gastrointestinal stromal tumor, HPF high-power fields, NIH
National Institutes of Health
a Size is based on single largest dimension
bMitotic index should be standardized based on surface area examined
and measured in the most proliferative area of the tumor
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Mutational Status
Certain mutations in KIT and platelet-derived growth factor
receptor alpha (PDGFRA) are known to have prognostic or
predictive implications. For example, KIT exon 9 mutations
and exon 11 deletions involving codons 557–558 are associ-
ated with poor outcome, and the PDGFRAmutation D842V is
associated with resistance to imatinib [11, 15, 26–29].
However, conflicting data have been published with regard
to mutational status and prognosis in resected localized GIST
[11, 15, 18, 30–41]. Ernst et al. first reported thatKITmutation
was associated with decreased survival (p=0.001) [30],
whereas Kim et al. found a correlation between the presence
of KIT mutation and RFS (overall risk, 5.6) [33]. Similarly,
Taniguchi et al. concluded that KITmutation was an indepen-
dent prognostic factor for OS and disease-specific survival
(DFS) [31]. Deletion of codons 557–558 was found to be an
independent prognostic factor in multivariate analysis (rela-
tive risk, 2.57; 95 % CI, 1.25 to 5.31) [11], which was
subsequently confirmed [39]. DeMatteo et al. demonstrated
that the absence of point mutation or insertion in KIT exon 11
and deletions of codon 557 or 558 in KIT exon 11 were
significant predictors of recurrence in univariate analysis
(p≤0.002), but not multivariate analysis. In contrast, Singer
et al. had shown earlier that the presence of KIT exon 11
deletion or insertion was an adverse independent prognostic
factor for DFS (HR, 4; p=0.006) [32]. However, Rutkowski
et al. [18], Tzen et al. [35], and Koay et al. [37] reported no
correlation between mutational status (presence of KIT exon
11 mutation, mutation type) and DFS, risk of recurrence, or
patient outcome, respectively. In the analysis performed by
Gold et al., incorporation of mutational status did not improve
the accuracy of their nomogram [3], but data on mutational
status were not available for one of the three data sets used to
develop this nomogram [11, 15, 19].
Corless and colleagues analyzed the pathological and
molecular features associated with outcome in the
ACOSOG Z9001 trial. Three hundred twenty-eight patients
were randomized to the placebo arm and 317 to the ima-
tinib arm. Six hundred forty-five tumor specimens were
available for mitotic rate or mutational analysis. On multi-
variate analysis of patients within the placebo arm, tumor
size, small bowel location, and mitotic rate were associated
with RFS. Mutational status was not associated with RFS
[42].
Further analysis in other large series with long-term follow-
up will be required to better define any role of mutational
status into GIST risk stratification systems.
Conclusions
Despite their undoubted utility and applicability, all of these
methods for GIST risk assessment have limitations. The cur-
rently available risk stratification schemes for patients with
resectable GIST are relatively straightforward and reliable.
The application of these schemes can reduce the overtreatment
Table 2 AFIP criteria for GIST
risk assessment
Adapted with permission from





a Tumor categories with very
small numbers of cases
Tumor parameter Patients with progressive disease during
follow-up and characterization of malignant
potential (%)
Group Tumor size (cm) Mitotic count (per 50 HPF) Gastric GIST Small intestinal GIST
1 ≤2 ≤5 0, none 0, none
2 >2 to ≤5 ≤5 1.9, very low 4.3, low
3a >5 to ≤10 ≤5 3.6, low 24, moderate
3b >10 ≤5 12, moderate 52, high
4 ≤2 >5 0a 50a
5 >2 to ≤5 >5 16, moderate 73, high
6a >5 to ≤10 >5 55, high 85, high
6b >10 >5 86, high 90, high
Table 3 Joensuu criteria for GIST risk assessment
Risk category Tumor size (cm) Mitotic index
(per 50 HPF)
Primary tumor site
Very low <2 ≤5 Any
Low 2.1–5 ≤5 Any
Intermediate 2.1–5 >5 Gastric
<5 6–10 Any
5.1–10 ≤5 Gastric






Adapted with permission from Joensuu [23]
GIST gastrointestinal stromal tumor, HPF high-power fields
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of patients with fully resected GISTand in patients with low-risk
disease that has likely been cured by surgery. However, a major
point regarding these systems is the application of cut points for
mitotic count and tumor size and whether these are optimal. For
instance, the cut points for mitotic count categorization could
lead to markedly different estimations of recurrence for patients
with a mitotic count close to 5 mitoses per 50 HPF. Furthermore,
no reference is made to whether the mitotically most active area
of a tumor should be evaluated. The evaluation of mitotic count
can be subjective and vary between observers. Furthermore, the
number of mitoses detected is dependent on tissue fixation time
and different-sized microscopic HPFs [43]. Tumor size determi-
nation can also potentially be affected when the specimen is
measured in relation to the time of resection until fixation.
Maki has suggested a simple way to stratify the risk for
primary GIST, using the “rule of fives” for low- and high-risk
disease [44]. Intermediate- to high-risk gastric GISTs are both
>5 cm in size and have >5 mitoses per 50 HPF. Furthermore,
non-gastric GISTs are high risk if they are either >5 cm or
have >5mitoses per 50HPF. This simple rule allows all GISTs
with a >50% risk of recurrence to be categorized as well as the
intermediate-risk group of 5–10 cm small bowel GISTs with
low mitotic rate (AFIP group 3a). However, caution should be
emphasized, as this is a much simplified stratification strategy.
Despite their limitations, it is clear that the three widely
used risk stratification systems are easily applicable and accu-
rate in predicting risk of recurrence in patients who have
undergone surgery for localized GIST. It is likely that risk
stratification in patients with localized GIST will continue to
evolve over the next few years, with the potential incorpora-
tion of mutational status and further data regarding follow-up
of patients treated with adjuvant imatinib.
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